Oryzon Genomics S.A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, … Read more
Market Cap & Net Worth: Oryzon Genomics S.A (ORYZF)
Oryzon Genomics S.A (PINK:ORYZF) has a market capitalization of $244.44 Million ($244.44 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #15375 globally and #6039 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oryzon Genomics S.A's stock price $3.10 by its total outstanding shares 78853122 (78.85 Million).
Oryzon Genomics S.A Market Cap History: 2020 to 2025
Oryzon Genomics S.A's market capitalization history from 2020 to 2025. Data shows change from $283.87 Million to $244.44 Million (-3.41% CAGR).
Oryzon Genomics S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oryzon Genomics S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
22.82x
Oryzon Genomics S.A's market cap is 22.82 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $283.87 Million | $9.52 Million | -$3.40 Million | 29.81x | N/A |
| 2021 | $315.41 Million | $10.62 Million | -$4.69 Million | 29.71x | N/A |
| 2022 | $205.02 Million | $15.70 Million | -$4.23 Million | 13.06x | N/A |
| 2023 | $134.05 Million | $14.19 Million | -$3.35 Million | 9.45x | N/A |
| 2024 | $167.96 Million | $7.36 Million | -$3.67 Million | 22.82x | N/A |
Competitor Companies of ORYZF by Market Capitalization
Companies near Oryzon Genomics S.A in the global market cap rankings as of March 19, 2026.
Key companies related to Oryzon Genomics S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oryzon Genomics S.A Historical Marketcap From 2020 to 2025
Between 2020 and today, Oryzon Genomics S.A's market cap moved from $283.87 Million to $ 244.44 Million, with a yearly change of -3.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $244.44 Million | +45.54% |
| 2024 | $167.96 Million | +25.29% |
| 2023 | $134.05 Million | -34.62% |
| 2022 | $205.02 Million | -35.00% |
| 2021 | $315.41 Million | +11.11% |
| 2020 | $283.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Oryzon Genomics S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.44 Million USD |
| MoneyControl | $244.44 Million USD |
| MarketWatch | $244.44 Million USD |
| marketcap.company | $244.44 Million USD |
| Reuters | $244.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.